JBIO Jade Biosciences, Inc.
Price Chart
Executive Summary
Jade Biosciences reported Q1 2026 EPS of -$0.57, missing consensus of -$0.52 by 9.6%. Net loss widened to $40.4M from $38.2M YoY as R&D spend increased 80% to $36.1M. Cash burn continues ($311M vs $336M in Dec 2025), but the pipeline focus remains on upcoming Phase 1 data for JADE101 at the ERA Congress.
Key Financial Metrics
Actionable Insight
Monitor the upcoming Phase 1 data presentation for JADE101 at the ERA Congress for clinical proof-of-concept; data could be a major catalyst if safety/efficacy are favorable. The EPS miss is secondary for a pre-revenue biotech.
Key Facts
- Q1 2026 GAAP EPS -$0.57 vs consensus -$0.52 (miss of -9.6%)
- Cash, cash equivalents and investments: $311.3M as of March 31, 2026 (vs $336.2M at year-end 2025)
- Net loss: $40.4M in Q1 2026 vs $38.2M in Q1 2025
- R&D expenses: $36.1M, up 80% YoY
- Phase 1 interim biomarker data for JADE101 to be presented in an oral session at the 63rd ERA Congress
- Phase 2 trial for JADE101 in IgAN expected to start Q2 2026
- JADE201 Phase 1 in RA expected to start Q2 2026
- Appointed Edward R. Conner, M.D. as CMO; promoted Dr. Andrew King to President, R&D
Financial Impact
Net loss increased 6% YoY to $40.4M; cash burn of ~$25M in Q1 2026
Risk Factors
- Clinical failure or delay of JADE101 Phase 2 or JADE201 Phase 1
- Cash runway may shorten if development costs escalate faster than expected
- Dilution from convertible notes (fair value changes impacted net loss in prior quarters)
Market Snapshot
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-211973 |
| Document: d108669d8k.htm | 0001193125-26-211973 |
| Document: 0001193125-26-211973-index-headers.html | 0001193125-26-211973 |
| Document: 0001193125-26-211973-index.html | 0001193125-26-211973 |
| Document: 0001193125-26-211973.txt | 0001193125-26-211973 |
| 8-K Data (Synthetic) | 0001193125-26-211973 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 5, 2026
4d ago
|
Press Release
| $16.91 awaiting T+1 | awaiting T+1 | — | $14.98 (+11.41%) |
|
Jun 4, 2026
5d ago
|
8-K
| $17.52 awaiting T+1 | awaiting T+1 | — | $14.98 (+14.50%) |
|
Jun 4, 2026
5d ago
|
424B5
| $17.52 awaiting T+1 | awaiting T+1 | — | $14.98 (+14.50%) |
|
Jun 4, 2026
6d ago
|
Press Release
| $17.74 $16.94 | ▲ +4.51% | ▲ +1.91% | $14.98 (+15.56%) |
|
Jun 3, 2026
6d ago
|
424B5
| $17.74 $16.94 | ▲ +4.51% | ▲ +1.94% | $14.98 (+15.56%) |
|
Jun 3, 2026
6d ago
|
Press Release
| $17.74 $16.94 | ▲ +4.51% | ▲ +1.94% | $14.98 (+15.56%) |
|
Jun 1, 2026
8d ago
|
8-K
| $18.59 $17.75 | ▼ −4.52% | ▼ −4.66% | $14.98 (−19.42%) |
|
May 26, 2026
14d ago
|
Press Release
| $21.50 $20.84 | ▼ −3.07% | ▼ −3.62% | $14.98 (−30.33%) |
|
May 18, 2026
23d ago
|
EFFECT
| $22.01 $21.88 | ▲ +0.59% | ▼ −0.06% | $14.98 (+31.94%) |
|
May 7, 2026
4w ago
|
S-3
| $25.81 $24.86 | ▲ +3.68% | ▲ +3.91% | $14.98 (+41.96%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access